Kinetics of B Cell Response in Infants Menjugate Vaccination

Phase 4CompletedNCT00310700

Novartis75 enrolled

Overview

Kinetics of B cell response in infants Menjugate vaccination

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Prevention of Meningococcal Infection

Interventions

Meningococcal C conjugate vaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 8 WeeksMax age: 11 WeeksHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy infants Exclusion Criteria: * previously ascertained or suspected disease caused by N. meningitidis * previous household contact with an individual with a positive culture of N. meningitidis serogroup C

Locations (1)

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital

Oxford, Oxon, United Kingdom

Outcomes

Primary Outcomes

To establish at which day meningococcal C specific B cells are detectable in the blood of healthy infants following first and third immunisation with MenC Conjugate Vaccine as determined by Men C specific B-cell ELISPot assay.

Secondary Outcomes

To establish how long the B cells persist in the blood

To note the difference between plasma cell response following the first and third MenC vaccination.

To determine the immune response to Neisseria meningitidis serogroup C 26-34 days after the third immunisation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.